Edwards Lifesciences suspends AAA (abdominal aortic aneurysm) trials and sales
This article was originally published in Clinica
Executive Summary
Just weeks after it began trading on the New York Stock Exchange as a separate company from its former parent, Baxter International, Edwards Lifesciences has suspended sales outside the US of its Lifepath AAA endovascular graft system.